GlassScriptPhysician profile
David Lee Shriner
NPI 1609884915
$1,786.15
in general payments reported to CMS, 2019-2025
22 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2020: $45.77 · 2022: $591 · 2023: $393 · 2024: $290 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $834.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $834.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $957.37 | 2019-2025 | Rinvoq, Skyrizi |
| Lilly USA, LLC | $189.37 | 2022-2024 | Olumiant, Taltz |
| Sun Pharmaceutical Industries INC. | $68.47 | 2019-2022 | |
| Incyte Corporation | $55.59 | 2023-2025 | Opzelura |
| Dermavant Sciences, INC. | $54.36 | 2023-2024 | Vtama |
| Journey Medical Corporation | $46.70 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.43 | 2022-2024 | Spevigo |
| Ucb, INC. | $39.99 | 2020-2025 | Bimzelx |
| Biofrontera INC. | $37.84 | 2022-2025 | |
| Nabriva Therapeutics, Plc | $37.42 | 2022 | |
| Leo Pharma INC. | $36.37 | 2019 | |
| Fresenius Kabi USA, LLC | $29.59 | 2023 | Idacio |
| Revance Therapeutics, INC. | $27.23 | 2024 | Daxxify |
| Novartis Pharmaceuticals Corporation | $23.59 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $21.22 | 2023 | Libtayo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $19.18 | 2022 | |
| Kyowa Kirin, INC. | $18.64 | 2022 | |
| Convatec INC. | $18.60 | 2024 | |
| Mayne Pharma Commercial LLC | $18.53 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $15.49 | 2019 | |
| Aclaris Therapeutics, INC. | $15.08 | 2019 | |
| Genentech USA, INC. | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Shriner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.